Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
IQVIA HOLDINGS INC. shows stable business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +8% YoY in Q1 FY2026.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 20d ago
IQV's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on IQV.
Free accounts see more of this; Premium sees all of it.
Reported figures for IQVIA HOLDINGS INC. — research only, not investment advice.
Updated
What happened recently for IQVIA HOLDINGS INC. (IQV) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
IQV's AI investment thesis
Upgrade to Premium for IQV's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$275.02
Market cap
$45.90B
Profitable
Yes
Revenue $4.15B
Net income
$274.00M
FY Sep 15, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for IQVIA HOLDINGS INC. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow IQVIA HOLDINGS INC. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
The shift from broad-spectrum drugs to gene-level targeting is concentrating value in a surprisingly narrow set of platform companies.
The tools to read, edit, and deliver on the genome are maturing faster than the market prices in.
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.